Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 16 (2), 152-60

Antiplatelet Therapy - A Summary for the General Physicians

Affiliations
Review

Antiplatelet Therapy - A Summary for the General Physicians

Jecko Thachil. Clin Med (Lond).

Abstract

Platelets play a very important role in physiological haemostasis and thrombus formation. Platelet aggregation is the key pathophysiological factor in the development of arterial ischaemic events, including coronary artery disease, cerebrovascular accidents and peripheral arterial disease. As such, antiplatelet therapy plays a very important role in preventing recurrent events in the individuals who are affected by one of these conditions. Until recently, the repertoire of antiplatelet therapy was limited to aspirin and clopidogrel. However, this landscape has changed dramatically with the advent of newer and more potent agents, prasugrel and ticagrelor and also the glycoprotein IIb/IIIa antagonists. This armamentarium is likely to expand further with the advent of protease-activated receptor-1 antagonists and the intravenous cangrelor. This review summarises the different agents available and some practical considerations for their use from a general physician's perspective.

Keywords: Platelets; antiplatelet aspirin; clopidogrel; platelets; prasugrel; ticagrelor.

Figures

Fig 1.
Fig 1.
A practical algorithm for the management of procedures in patients receiving dual antiplatelet therapy. The dual agents are usually aspirin and a P2Y12 inhibitor. Bridging is with a glycoprotein IIb/IIIa blocker.
Fig 2.
Fig 2.
Algorithm for the management of triple therapy including the ­duration.

Similar articles

See all similar articles

Cited by 3 articles

MeSH terms

Feedback